A schedule of recombinant Mpl ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation

Experimental Hematology

Volumn 29, Issue 12, 2001, Pages 1425-1431

  Abushullaih, Basel A ^a,b   Pestina, Tamara I ^a   Srivastava, Deo Kumar ^a   Jackson, Carl W ^a   Daw, Najat C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DEATH; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANIMALS; BONE MARROW CELLS; CARBOPLATIN; FEMALE; HEMATOPOIESIS; KINETICS; MICE; MICE, INBRED C57BL; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THROMBOPOIETIN; TIME FACTORS; WHOLE-BODY IRRADIATION;

MURINAE;

EID: 0035652689     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00748-2     Document Type: Article

References (30)

1. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
2. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
3. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
4. The purification of megapoietin; A physiological regulator of megakaryocyte growth and platelet production
5. Thrombopoietin
6. Thrombopoietin; Biology and clinical potentials
7. Thrombopoietin; An update on therapeutic potential
8. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation
9. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation
10. A double blind, placebo controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
11. A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration
12. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
13. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice
14. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow repopulating cells
15. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice
16. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice
17. Stimulation of thrombocytopoiesis in irradiated mice
18. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice
19. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates
20. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization
21. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation
22. Role of c-mpl in early hematopoiesis
23. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis
24. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro
25. Thrombopoietin behaves as a survival factor and suppresses apoptosis in a human growth factor dependent cell line M07e
26. - bone marrow cells with multilineage potential at the single-cell level; key role of thrombopoietin
27. Mpl Ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors
28. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways
29. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets
30. The haemopoietic effects of thrombopoietin administered post-myelosuppressive carboplatin therapy compared to either pre- and post- or pre-chemotherapy